Evelo Biosciences Inc. (EVLO)
$0.00
$-0.04
(-99.75%)
As on 31-Aug-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-70 Mln
-
ROE
-62.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-83.8
-
Face value
--
-
Shares outstanding
18,982,837
8 Years Aggregate
CFO
$-499.56 Mln
EBITDA
$-493.16 Mln
Net Profit
$-593.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evelo Biosciences (EVLO)
| -- | -- | -- | -- | -97.5 | -94.6 | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Evelo Biosciences (EVLO)
| -99.8 | -73.5 | -49.8 | 197.8 | -68.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Evelo Biosciences (EVLO)
|
0.0 | 0.0 | 0.0 | -82.4 | -- | -- | -- | 3.5 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Evelo Biosciences (EVLO)
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate,... which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read more
-
President, Secretary, Principal Executive, Financial and Accounting Officer & Director
Mr. Craig R. Jalbert CIRA
-
President, Secretary, Principal Executive, Financial and Accounting Officer & Director
Mr. Craig R. Jalbert CIRA
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Evelo Biosciences (EVLO)
What is the current share price of Evelo Biosciences Inc (EVLO) Today?
The share price of Evelo Biosciences Inc (EVLO) is $0.00 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Evelo Biosciences Inc (EVLO) has given a return of -97.52% in the last 3 years.
What is the current PB & PE ratio of Evelo Biosciences Inc (EVLO)?
Since, TTM earnings of Evelo Biosciences Inc (EVLO) is negative, P/E ratio is not available.
The P/B ratio of Evelo Biosciences Inc (EVLO) is 3.51 times as on 27-Aug-2026, a 32 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.08 |
-1.77 |
2021 |
-0.13 |
1.87 |
2020 |
-0.30 |
0.93 |
2019 |
-0.08 |
0.11 |
2018 |
-0.38 |
0.15 |
What is the 52 Week High and Low of Evelo Biosciences Inc (EVLO)?
The 52-week high and low of Evelo Biosciences Inc (EVLO) are Rs 0.00 and Rs 0.00 as of 02-Sep-2026.
What is the market cap of Evelo Biosciences Inc (EVLO)?
Evelo Biosciences Inc (EVLO) has a market capitalisation of $ 0 Mln as on 27-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Evelo Biosciences Inc (EVLO)?
Before investing in Evelo Biosciences Inc (EVLO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.